Not provided
Not provided
Not provided
Not provided
Not provided
Insufficient participant enrollment due to dwindling case numbers/case severity
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Applied Health Research Centre | OTHER |
Not provided
Not provided
Not provided
Not provided
The rapid development of safe and effective COVID-19 treatment is a global health priority. Numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. Consequently, there is an urgent need to identify therapies that prevent mild COVID-19 cases in the community from becoming more severe. "Proning" or lying face down in bed has been shown to improve breathing and oxygen levels in COVID-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. The current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of COVID-19 from becoming more severe resulting in fewer hospitalizations and death. A randomized controlled trial will be used to reduce the risk of bias when testing this intervention. Unvaccinated or partially vaccinated adult patients with a positive COVID-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. Our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. We'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. The current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Self-proning | Experimental | Participants assigned to the intervention arm will receive a SMS link to a PDF containing instructions on proning/repositioning and information about its physiological benefits. They'll also receive a PDF with standard recommendations for treating COVID-19 at home. Participants will be encouraged to lie flat on their belly, on their side, or sit upright and rotate between these positions when lying down during the day and night. Participants will be sent a daily SMS "proning reminder" and asked to complete a secure REDCap survey regarding their proning activity. They'll be advised to prone and reposition for seven days minimum whenever they are lying down. Participants who have failed to reach their functional baseline after this time period will be advised to continue doing so. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days. |
|
| Standard care | No Intervention | Participants assigned to the comparator arm will receive a SMS link to a PDF with standard recommendations for treating COVID-19 at home. This includes antipyretics and analgesics for fever, myalgias, and headaches; hydration; and rest with advancement of activity as soon as tolerated. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self-proning | Other | Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night. |
| Measure | Description | Time Frame |
|---|---|---|
| Composite of hospitalization and all cause mortality | The primary outcome is a composite of hospital admission and all-cause mortality. This will be ascertained using telephone follow up and deterministic record linkage performed by the Institute for Clinical Evaluative Sciences (ICES) using their Discharge Abstract Database (DAD). | Up to 28 days post-randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalization | Up to 28 days post-randomization | |
| All cause mortality | Up to 28 days post-randomization | |
| Time to functional recovery in days |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility outcome: successful recruitment | Defined as >=50% of eligible participants agreeing to enrollment | Through study completion, on average one year |
| Feasibility outcome: successful retention of trial participants, |
Inclusion Criteria:
Age ≥18 years
Positive SARS-CoV-2 PCR test
Presence of two or more of the following criteria:
Age>55 years
Fever by history or at presentation
Cough
Dyspnea/shortness of breath
Fatigue necessitating daytime bed rest
One or more of the following medical conditions:
Tachycardia > 110 bpm
Oxygen saturation <94%
One or more of the following laboratory abnormalities:
Bilateral infiltrates or ground glass opacities on chest x-ray or CT scan
Socially and medically fit for discharge
Access to a smartphone
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Joseph's Health Centre | Toronto | Ontario | M6R 1B5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D003643 | Death |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Open label, pragmatic, randomized controlled internal pilot trial (vanguard phase)
Not provided
Not provided
Not provided
Not provided
|
Defined as: resolution of fever for 48 hours, significant symptom reduction and ability to perform most daily activities or return to work, if applicable, for two consecutive days. |
| Up to 28 days post-randomization |
| Use of antibiotics for respiratory illness | Up to 28 days post-randomization |
| Follow up emergency department assessment without hospital admission | Number of subsequent emergency department visits by study participants that relate to the initial COVID-19 presentation but do not result in hospital admission | Up to 28 days post-randomization |
Defined as <10% attrition rate
| Up to 28 days |
| Feasibility outcome: adherence to the intervention | Defined as self-proning and repositioning daily for >=75% of days of symptom duration. Adherence will be ascertained through daily survey of study participants. | Up to 28 days |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |